| Role of Neutrophils and Electro-bioluminescence in the Rehabilitation (NCT06209229) | MIPO Clinic | 2022-05-01 |
| TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer (NCT05284994) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-03-11 |
| A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors (NCT05082610) | Hummingbird Bioscience | 2022-02-28 |
| Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population (NCT05863052) | University of Oklahoma | 2022-01-31 |
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC (NCT04984811) | NeoImmuneTech | 2021-11-15 |
| Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy (NCT04253964) | Wake Forest University Health Sciences | 2020-07-01 |
| First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b (NCT04396340) | Mersana Therapeutics | 2020-05-11 |
| Metabolic and Microbial Profiling of Lung Cancer (NCT03998189) | Wake Forest University Health Sciences | 2019-10-11 |
| Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC (NCT03769805) | The First Affiliated Hospital with Nanjing Medical University | 2019-06-15 |
| Study of Lorlatinib in ROS1 Rearranged NSCLC (NCT03612154) | National Cancer Center, Korea | 2019-05-02 |
| CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology (NCT03940846) | Maastricht University | 2019-03-01 |
| TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors (NCT03778814) | Second Affiliated Hospital of Guangzhou Medical University | 2018-12-01 |
| A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (NCT02905591) | Joseph J. Cullen, MD, FACS | 2018-11-16 |
| A Mobile Supportive Care App for Patients With Metastatic Lung Cancer (NCT03512015) | Bocconi University | 2018-05-15 |
| Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer (NCT03450330) | Dizal Pharmaceuticals | 2018-04-16 |
| IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer (NCT03258671) | LuBing | 2017-10-01 |
| Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC (NCT03256721) | Fuzhou General Hospital | 2017-08-16 |
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT03088540) | Regeneron Pharmaceuticals | 2017-05-29 |
| A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC (NCT02981108) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2017-05-08 |
| Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer (NCT02963610) | Fox Chase Cancer Center | 2017-03-29 |
| EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC (NCT02988141) | Jianxing He | 2017-03-01 |
| Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC (NCT03044626) | AIO-Studien-gGmbH | 2017-02-10 |
| Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer (NCT02994576) | Gustave Roussy, Cancer Campus, Grand Paris | 2016-12-12 |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) (NCT02973789) | NovoCure GmbH | 2016-12-01 |
| A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer (NCT02967133) | Alliance Foundation Trials, LLC. | 2016-12-01 |
| Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M (NCT02972333) | Shandong Cancer Hospital and Institute | 2016-12-01 |
| EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism (NCT03002844) | Shanghai Pulmonary Hospital, Shanghai, China | 2016-12-01 |
| cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China (NCT02980536) | Berry Genomics Co., Ltd. | 2016-11-01 |
| Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer (NCT02974933) | Wuling Ou | 2016-11-01 |
| Effects of Acupuncture Stimulation on Systemic Inflammation (NCT02951611) | RenJi Hospital | 2016-11-01 |
| Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations (NCT02954523) | Chul Kim | 2016-10-01 |
| MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors (NCT02669914) | Washington University School of Medicine | 2016-09-12 |
| Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) (NCT02419170) | Washington University School of Medicine | 2016-07-01 |
| Skeletal Muscle Atrophy and Dysfunction in Human Cancer (NCT02949076) | University of Vermont | 2016-07-01 |
| Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer (NCT03050411) | Peking University Third Hospital | 2016-05-01 |
| Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) (NCT02705339) | Washington University School of Medicine | 2016-05-01 |
| Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors (NCT02537561) | Washington University School of Medicine | 2015-12-01 |
| SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer (NCT02562027) | Washington University School of Medicine | 2015-09-11 |
| Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) (NCT02342353) | Washington University School of Medicine | 2015-05-18 |
| Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NCT02299141) | Washington University School of Medicine | 2015-05-07 |
| Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression (NCT02431169) | Washington University School of Medicine | 2015-04-30 |
| Pazopanib in Molecularly Selected Patients With Advanced NSCLC (NCT02193152) | Washington University School of Medicine | 2015-04-27 |
| Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy (NCT02972216) | Yung Shin Pharm. Ind. Co., Ltd. | 2014-11-01 |
| Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients (NCT02010047) | British Columbia Cancer Agency | 2013-12-01 |
| Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (NCT01999673) | Peregrine Pharmaceuticals | 2013-12-01 |
| Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) (NCT01312337) | Samsung Medical Center | 2010-09-01 |
| Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis (NCT01301560) | Samsung Medical Center | 2008-06-01 |